Trial Profile
A Randomized, Blind,Single dose, Parallel control Phase I Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Full human recombinant monoclonal antibody against RANKL for injection and Prolia in Healthy Volunteers
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Aug 2018
Price :
$35
*
At a glance
- Drugs KN-012 (Primary) ; Denosumab
- Indications Osteoporosis
- Focus Pharmacokinetics
- 10 Aug 2018 New trial record